Arrowhead Pharmaceuticals, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €646.04M +62.1% -€51.88M -79.6% -8.0% +0.56 pp -€189.87M -43.4% -29.4% +0.55 pp
    (estimated) €398.61M +35.5% -€253.71M -37.5% -63.6% +0.74 pp -€335.42M +15.3% -84.1% +0.15 pp
    (estimated) €294.19M -3.0% -€406.19M +14.0% -138.1% -0.21 pp -€290.81M +31.9% -98.9% -0.26 pp
    (estimated) €303.29M -51.5% -€356.32M +9,330.0% -117.5% -1.2 pp -€220.40M -192.1% -72.7% -1.1 pp
    (estimated) €624.77M +106.3% -€3.78M -99.3% -0.6% +1.7 pp €239.30M -187.3% 38.3% +1.3 pp
    €302.88M +47.5% -€511.34M +192.0% -168.8% -0.84 pp -€274.12M -1,506.7% -90.5% -1.0 pp
    €205.34M -1.0% -€175.09M +16.3% -85.3% -0.13 pp €19.49M -127.4% 9.5% +0.44 pp
    €207.46M +75.9% -€150.54M +25.3% -72.6% +0.29 pp -€71.10M -142.8% -34.3% -1.8 pp
    €117.95M +57.2% -€120.14M +66.6% -101.9% -0.058 pp €166.15M -333.5% 140.9% +2.4 pp
    €75.05M -47.9% -€72.12M -224.4% -96.1% -1.4 pp -€71.17M -145.1% -94.8% -2.0 pp
    €143.97M +945.7% €57.98M -224.8% 40.3% +3.8 pp €157.83M -504.0% 109.6% +3.9 pp
    €13.77M -48.6% -€46.44M +58.4% -337.3% -2.3 pp -€39.07M +185.9% -283.7% -2.3 pp
    €26.79M +19,736.5% -€29.32M -57.9% -109.5% +520 pp -€13.66M -73.5% -51.0% +380 pp
    €135.05K -58.6% -€69.71M -11.1% -51,614.6% -280 pp -€51.66M -5.0% -38,253.1% -220 pp
    €325.83K +118.3% -€78.42M +56.8% -24,068.3% +94 pp -€54.36M +89.1% -16,685.1% +26 pp
    €149.27K -39.7% -€50.01M +88.3% -33,503.0% -230 pp -€28.74M +79.9% -19,256.6% -130 pp
    €247.58K +97.6% -€26.56M +47.4% -10,729.2% +37 pp -€15.98M +26.1% -6,454.9% +37 pp
    €125.28K -50.4% -€18.02M +575.2% -14,383.6% -130 pp -€12.68M +176.2% -10,117.9% -83 pp
    €252.59K -52.2% -€2.67M -45.8% -1,056.6% -1.3 pp -€4.59M -30.1% -1,817.1% -5.8 pp
    €528.91K -83.6% -€4.92M -70.1% -931.2% -4.2 pp -€6.56M -49.5% -1,240.8% -8.4 pp
    €3.22M +189.5% -€16.47M -28.7% -511.7% +16 pp -€13.00M -43.4% -403.8% +17 pp
    €1.11M +7.9% -€23.11M -9.5% -2,078.7% +4.0 pp -€22.94M +16.4% -2,064.2% -1.5 pp
    €1.03M +102.9% -€25.53M +57.6% -2,477.7% +7.1 pp -€19.71M +66.8% -1,913.1% +4.1 pp
    €507.90K +0.8% -€16.20M +186.8% -3,190.4% -21 pp -€11.82M +64.4% -2,327.1% -9.0 pp
    €503.82K +200.9% -€5.65M +165.3% -1,121.6% +1.5 pp -€7.19M +411.0% -1,426.6% -5.9 pp
    €167.44K +∞% -€2.13M +2,521.8% -1,272.0% -13 pp -€1.41M +960.5% -840.0% -8.4 pp
    €0.00 -100.0% -€81.23K -61.3% N/A -€132.62K +49.3% N/A
    €1.93K -75.7% -€210.00K +32.5% -10,865.3% -89 pp -€88.84K +27.3% -4,596.5% -37 pp
    €7.94K -62.6% -€158.50K +35.1% -1,995.5% -14 pp -€69.78K +3.1% -878.6% -5.6 pp
    €21.22K -32.8% -€117.33K -123.2% -552.9% -22 pp -€67.68K +125.3% -318.9% -2.2 pp
    €31.56K -38.7% €505.80K -1,248.8% 1,602.8% +17 pp -€30.04K -23.7% -95.2% -0.19 pp
    €51.50K -21.2% -€44.03K -94.0% -85.5% +10 pp -€39.36K -1,111.6% -76.4% -0.82 pp
    €65.33K -€728.88K -1,115.7% €3.89K 6.0%

    Notifications